Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference
Planegg/Martinsried, December 19, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be attending the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco to be held from January 8-11, 2024.
J.P. Morgan Healthcare Conference
https://www.jpmorgan.com/about-us/events-conferences/health-care-conference
Date: January 8-11, 2024
Location: The Westin St. Francis Hotel, San Francisco, CA
Members of Medigene’s management team will be available for one-on-one meetings to showcase the Company’s unique scientific platform, product pipeline, execution of its corporate strategy, and 2024 plans. Please contact Pamela Keck at p.keck@medigene.com to schedule a meeting.
— end of press release —
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. Its End-to-End Platform, built on multiple proprietary and exclusive TCR generation and optimization, as well as product enhancement technologies, allows Medigene to create best-in-class, differentiated T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for safety, efficacy and durability. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com
Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
Email: investor@medigene.com
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
